Name | Bromisoval |
Synonyms | Bromisoval Bromvaletone Bromisovalum Bromvalerylurea BROMOVALERYLUREA BROMOISOVALERYLUREA RARECHEM AX KI 5046 LABOTEST-BB LT00134620 A-(BROMOISOVALERYL)UREA 1-(2-BROMOISOVALERYL)UREA ALPHA(BROMOISOVALERYL)UREA BROMO-ISO-VALERYLUREA (ALPHA) 2-bromo-N-carbamoyl-3-methylbutanamide (2S)-2-bromo-N-carbamoyl-3-methylbutanamide (2R)-2-bromo-N-carbamoyl-3-methylbutanamide |
CAS | 496-67-3 |
EINECS | 207-825-7 |
InChI | InChI=1/C6H11BrN2O2/c1-3(2)4(7)5(10)9-6(8)11/h3-4H,1-2H3,(H3,8,9,10,11)/t4-/m0/s1 |
InChIKey | CMCCHHWTTBEZNM-UHFFFAOYSA-N |
Molecular Formula | C6H11BrN2O2 |
Molar Mass | 223.07 |
Density | 1.6005 (rough estimate) |
Melting Point | 152 °C |
Water Solubility | 19.03g/L(temperature not stated) |
Solubility | DMSO (Slightly), Methanol (Slightly) |
Appearance | Solid |
Color | White to Off-White |
Merck | 14,1397 |
pKa | 10.54±0.70(Predicted) |
Storage Condition | Sealed in dry,Room Temperature |
Refractive Index | 1.5410 (estimate) |
Physical and Chemical Properties | White needle-like crystals. Melting point 147-149 ℃, soluble in alcohol, ether, acetone, insoluble in cold water. Soluble in hot water. No odor, slightly bitter taste. |
Use | This product is for scientific research only and shall not be used for other purposes. |
In vitro study | Bromisoval (BU) suppresses nitric oxide (NO) releasing and proinflammatory cytokine expression in lipopolysaccharide (LPS)-treat BV2 cells, a murine microglial cell line. Bromisoval suppresses LPS-inducing phosphorylation of signal transducer and activator of transcription 1 (STAT1) and expression of interferon regulatory factor 1 (IRF1). The Janus kinase 1 (JAK1) inhibitor filgotinib suppresses the NO release much more weakly than that of Bromisoval, although filgotinib almost completely prevents LPS-inducing STAT1 phosphorylation. Knockdown of JAK1, STAT1, or IRF1 does not affect the suppressive effects of Bromisoval on LPS-inducing NO. A combination of Bromisoval and filgotinib synergistically suppress the NO releasing. The mitochondrial complex I inhibitor rotenone, which does not prevent STAT1 phosphorylation or IRF1 expression, suppresses proinflammatory mediator expression less significantly than Bromisoval. Bromisoval and rotenone reduce intracellular ATP (iATP) levels to a similar extent. A combination of rotenone and filgotinib suppress NO release in LPS-treated BV2 cells as strongly as Bromisoval. |
In vivo study | Bromisoval (Bromvaletone) and carbromal are the most potent central depressants within each series. Depressant activities (ISD 50 values) and acute toxicities (LD 50 values) in male mice after intraperitoneal injection of Bromisoval are 0.35 (0.30-0.39) and 3.25 (2.89-3.62) mmol/kg, respectively. |
RTECS | YS3150000 |
Toxicity | LD50 in male mice (mmoles/kg): 3.25 i.p. (Mrongovius) |
NIST chemical information | Information provided by: webbook.nist.gov (external link) |
EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |
biological activity | Bromisoval (Bromovalerylurea, Isobromyl, Bromaral, BRN 1773255) is a bromoureide compound with hypnotic and sedative effects. It has anti-inflammatory activity. |
use | the product has sedative and mild hypnotic effects. it is effective 5 minutes after taking it. the action time lasts for 4 hours. it is not habitual and can be made into powder, tablet and injection. |
Production method | Using isoamyl alcohol as raw material, it is first oxidized to produce isovaleric acid, then brominated to produce α-bromoisovaleryl bromide, and finally condensed with urea to form bromoisovaleryl urea. |
category | toxic substances |
toxicity classification | poisoning |
acute toxicity | oral-rat LD50: 1000 mg/kg; Oral-mouse LD50: 2000 mg/kg |
flammability hazard characteristics | Thermal decomposition discharges toxic bromide and nitrogen oxide smoke |
storage and transportation characteristics | warehouse ventilation and low temperature drying |
fire extinguishing agent | water, dry powder, dry sand, carbon dioxide, foam, 1211 fire extinguishing agent |